from February 2013, HIV-positive patients will undergo tests of an AIDS vaccine developed in France, to investigate its effectiveness in humans, announced the public agency of Marseille hospitals.
after passing through several clinical trials, France health agencies adopted the opinion and will start with the e xperimentacion in humans who have the human immunodeficiency virus (HIV).
with this vaccine is expected to replace the current treatment that patients undergo HIV therapy called Triple. the scientist responsible for the vaccine, Erwann Loret said that to provide the treatment Triple for the 33 million HIV-infected people is impossible, vaccination is the only therapeutic treatment suitable AIDS , said Loret, director of the laboratory of structural biologyof Marseille, La Timone.
focalization of the Tat protein is a key element for the efficacy of this vaccine against AIDS, because the protein is what gives keep the virus in cells, says Dr. Loret our vaccine will deal directly with the shield of the infected cells .
vaccine aims to weaken the Tat protein, produce antibodies in the immune system and thus eliminate cells infected by the Virus of immunodeficiency human.
results will be known until 2015, when it can be shown the efficacy of the vaccine in humans, so far the in vitro research and in vivo has been excellent, and the positive results in experiments with monkeys have been more than favorable, and hope to counter the HIV virus in the human body.
